Gerresheimer cuts 2026 outlook citing project delays, production expansion costs (updated)

Gerresheimer AG

29/06/2026 11:57

Adds details on 2025 results, shares, paragraphs 2-3
June 29 (Reuters) - German medical packaging firm Gerresheimer GXIG.DE cut its margin outlook for 2026, saying project delays and operational issues including production ramp-ups weighed on earnings.
In a separate statement, the Duesseldorf-based company said its revenue in the 2025 financial year came at €2.3 billion  ($2.62 billion), broadly in line with an LSEG poll of analysts, but it said it will not pay a dividend for the period.
Its shares fell almost 10% following the announcement but recovered some losses and were down 3% by 1053 GMT, after losing almost 15% of their value since the beginning of the year.
Gerresheimer now expects an adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) margin of around 17% to 18% for the current year before M&A and refinancing activities, down from a previous forecast of 18% to 19%.
Gerresheimer also anticipates negative free cash flow of between €-50 million and €-100 million.



($1 = 0.8772 euros)

 (Reporting by Danny Callaghan and Paolo Laudani in Gdansk; Editing by Susan Fenton)
 ((Email: danny.callaghan@thomsonreuters.com))